Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Engage Grants Program

University of British Columbia

$25,000.00

Synthesis of hydroxyadamantanacetamide derivatives for the development of novel biomarkers

EF 2012-13

Résumé
Cancer ranks among the top leading causes of death in Canada. Approximately 42% of the Canadian population develops malignant tumors over their lifetime and 25% of the population is predicted to die as a result of cancer. The early detection of malignant tumor growth is critical for increasing survival rates. BioMark, a Canadian based medical technology company, focuses on developing new assays for early tumor detection. They have recently developed and commercialized an exciting new cancer diagnostic, the Acetylated Biomarker Assay (ABA) Red Alert technology. This assay detects spermine/spermidine N-acetyltransferase (SSAT), an enzyme that is up-regulated in solid tumors. Despite this exciting breakthrough, the technology is very expensive. BioMark is currently developing a significantly more cost effective in vitro diagnostic kit using monoclonal antibodies. Key for this project's success is the synthesis of gram quantities of two different hydroxyadamantanacetamide derivatives are required to establish a better antibody with high specificity. The desired chemicals are only available through custom synthesis and are, thus, prohibitively expensive. Furthermore, currently synthetic routes in the literature are highly inefficient. The goal of this project is to develop a concise and modular synthetic route to hydroxyadamantanacetamide derivatives that can be readily scalable. This will provide sufficient material for BioMark to explore the use of these compounds in the production of highly selective monoclonal antibodies for early tumor detection.
Programme
Engage Grants Program
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
429903-2012
Name nom
Sammis, Glenn
Department département
Chemistry
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2012
Competition year année de concours
2012
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1554
Committee name en
Pacific Internal Decision Committee
Committee name fr
Comité de décision interne pour le Pacifique
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
3700
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Organic chemistry
Research subject fr
Chimie organique
Partie
1
Nb partie
1
Application title
Synthesis of hydroxyadamantanacetamide derivatives for the development of novel biomarkers
Keyword
NSERC
Application summary
Cancer ranks among the top leading causes of death in Canada. Approximately 42% of the Canadian population develops malignant tumors over their lifetime and 25% of the population is predicted to die as a result of cancer. The early detection of malignant tumor growth is critical for increasing survival rates. BioMark, a Canadian based medical technology company, focuses on developing new assays for early tumor detection. They have recently developed and commercialized an exciting new cancer diagnostic, the Acetylated Biomarker Assay (ABA) Red Alert technology. This assay detects spermine/spermidine N-acetyltransferase (SSAT), an enzyme that is up-regulated in solid tumors. Despite this exciting breakthrough, the technology is very expensive. BioMark is currently developing a significantly more cost effective in vitro diagnostic kit using monoclonal antibodies. Key for this project's success is the synthesis of gram quantities of two different hydroxyadamantanacetamide derivatives are required to establish a better antibody with high specificity. The desired chemicals are only available through custom synthesis and are, thus, prohibitively expensive. Furthermore, currently synthetic routes in the literature are highly inefficient. The goal of this project is to develop a concise and modular synthetic route to hydroxyadamantanacetamide derivatives that can be readily scalable. This will provide sufficient material for BioMark to explore the use of these compounds in the production of highly selective monoclonal antibodies for early tumor detection.